Bolt Biotherapeutics
Logotype for Bolt Biotherapeutics Inc

Bolt Biotherapeutics (BOLT) investor relations material

Bolt Biotherapeutics Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Bolt Biotherapeutics Inc
Q3 2026 earnings summary12 Nov, 2026

Executive summary

  • Q3 net loss narrowed to $4.4M from $7.1M YoY as operating expenses declined; collaboration revenue was $0.

  • The October 23 Prana acquisition and $120M private placement shifted development focus to PRA-216 and the INSPIRE multispecific pipeline.

Financial highlights

  • Q3 collaboration revenue was $0 versus $2.2M; 9M revenue was $31K versus $5.2M.

  • Q3 operating expenses were $4.7M versus $9.9M; 9M expenses were $20.7M versus $34.2M, including a $0.8M impairment charge in 2026.

  • Q3 operating loss was $4.7M versus $7.7M; net loss was $4.4M versus $7.1M. 9M operating loss was $20.7M versus $29.0M; net loss was $19.5M versus $26.7M.

  • Q3 basic and diluted loss per share was $2.25 versus $3.72; 9M loss per share was $10.09 versus $13.94.

  • Q3 R&D expense fell to $2.2M from $6.5M and G&A to $2.5M from $3.3M, reflecting lower program activity, headcount and personnel costs, restructuring and R&D tax incentives.

Outlook and guidance

  • PRA-216 is in Phase 2 for asthma, COPD and atopic dermatitis; a fourth Phase 2 study in eosinophilic esophagitis is planned.

  • Initial PRA-216 Phase 2 data and proof-of-concept data across four studies are expected beginning in 2Q 2027; a second wholly owned INSPIRE program is expected to enter clinical testing and generate initial data in 2H 2027.

  • Based on the operating plan and October financing, funding is expected into 2028, subject to Series D conversion and successful delivery of common shares.

  • Significant operating losses and R&D spending are expected to continue; future funding needs depend on clinical progress, development costs and access to financing or partnerships.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Bolt Biotherapeutics earnings date

Logotype for Bolt Biotherapeutics Inc
Q4 202611 Mar, 2027
Bolt Biotherapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Bolt Biotherapeutics earnings date

Logotype for Bolt Biotherapeutics Inc
Q4 202611 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Bolt Biotherapeutics Inc. is a clinical-stage biotechnology company engaged in developing innovative immunotherapies for cancer treatment. The company's proprietary technology, Boltbody Immune-stimulating Antibody Conjugate, represents a novel approach in immuno-oncology, aiming to transform "cold" tumors into "hot" tumors by engaging and activating myeloid cells to directly attack tumor cells. Bolt Biotherapeutics is advancing its lead clinical candidate, BDC-1001, a HER2-targeting Boltbody ISAC for the treatment of patients with HER2-positive solid tumors. Additionally, the company is developing BDC-3042, a myeloid modulating agonistic antibody aimed at reprogramming tumor-associated macrophages to enhance anti-tumor immunity, with plans to enter clinical trials. The company is headquartered in Redwood City, California, and its shares are listed on the Nasdaq.